Administration of IL-10 in vitro prevents TNF-α stimulated expression of MAdCAM-1 and also blocks lymphocyte adhesion on endothelial cells to the same level as dexamethasone treatment, currently a key therapy in IBD [36]. Here, IL10 is linked to inflammatory bowel disease.